TIGERMED (03347.HK): Controlling Shareholders Ye Xiaoping and Cao Xiaochun Receive Warning Letter and Administrative Penalty Pre-notice Over Shareholding-change Disclosure Violations; RMB 1 Million Fine Proposed
- Ye Xiaoping and Cao Xiaochun are each fined RMB 500,000, totalling RMB 1 million.
- The Warning Letter concerns their voluntary reduction of shareholdings on 7 December 2022, which caused the aggregate change in equity interest to decrease by 1% and was not disclosed in a timely manner; the Zhejiang Regional Office requires them to submit a written report within 10 working days from the date of receipt of the decision.
- The Prior Notice concerns the failure to disclose the Simplified Form of Equity Change Report in a timely manner after their aggregate shareholding in voting shares issued by Tigermed cumulatively changed by 5% on 20 September 2019; the Company stated that the matters do not fall within the circumstances of mandatory delisting for material violations on ChiNext or the other risk warning circumstances under Rule 9.4.
NewTimeSpace News: On 11 September 2026, Hangzhou Tigermed Consulting Co., Ltd. (stock code: 03347.HK; A-share stock code: 300347.SZ) announced that its actual controllers Ye Xiaoping and Cao Xiaochun on 11 September 2026 received a decision on taking measures of issuing a warning letter against Ye Xiaoping and Cao Xiaochun (the "Warning Letter") and a Prior Notice of Administrative Penalty (Zhe Zheng Fa Zi [2026] No. 21) (the "Prior Notice") issued by the Zhejiang Regional Office of the China Securities Regulatory Commission (CSRC).
The Warning Letter states that Ye Xiaoping and Cao Xiaochun, as the actual controllers of the Company, voluntarily reduced their shareholdings on 7 December 2022 with the aggregate change in equity interest decreasing by 1%, and failed to disclose the change in equity interest in a timely manner, only disclosing the relevant information on 12 May 2026, in violation of Article 13(3) of the Measures for the Administration of the Takeover of Listed Companies. The Zhejiang Regional Office decided to take the regulatory measure of issuing a warning letter to the two individuals and to record the matter in the securities and futures market integrity database, and they are required to submit a written report within 10 working days from the date of receipt of the decision.
The Prior Notice states that on 20 September 2019, the aggregate shareholding of Ye Xiaoping, the controlling shareholder of Tigermed, and his person acting in concert Cao Xiaochun in the voting shares already issued by Tigermed cumulatively changed by 5%, and the Simplified Form of Equity Change Report was not disclosed in a timely manner and was only supplementarily disclosed on 12 May 2026. The Zhejiang Regional Office proposed to give a warning to Ye Xiaoping and Cao Xiaochun and impose a fine of RMB 1 million, of which RMB 500,000 is imposed on Ye Xiaoping and RMB 500,000 on Cao Xiaochun.
The Company stated that the above matters relate to information disclosure in the course of the actual controllers' historical shareholding changes, are unrelated to the Company's operations and will not affect its normal production and operating activities, and that as at the date of this announcement the Company's production and operating conditions remain normal. The Company also stated that the circumstances identified do not fall within the circumstances of mandatory delisting for material violations as stipulated in the Rules Governing the Listing of Stocks on the ChiNext Board of the Shenzhen Stock Exchange, nor do they fall within the other risk warning circumstances under Rule 9.4. The Warning Letter is an administrative regulatory measure, while the Prior Notice is a pre-procedure for an administrative penalty decision, and the final result of the administrative penalty shall be subject to the Administrative Penalty Decision to be issued by the Zhejiang Regional Office.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Tigermed (03347.HK): Has repurchased A-shares with a total consideration of approximately RMB 824 million
- TIGERMED(03347.HK) will spend CNY 175.37 million to repurchase 4.44 million shares on Jun 12, 2026
- TIGERMED (03347.HK): Directors and Controlling Shareholders Ye Xiaoping and Cao Xiaochuan Placed Under CSRC Investigation
- HS Optimus Holdings Proposes SGD4.2 Million Acquisition of 30% Stake in Medicorp Plus Put Option for Additional 19% Equity